Jam

Innovent Biologics initiated a Phase 3 trial (GLORY-OSA) in China for mazdutide, a dual GCG and GLP-1 receptor agonist. The study will evaluate the drug’s efficacy and safety in Chinese patients with obesity and moderate-to-severe obstructive sleep apnea (OSA). Mazdutide has shown potential in weight loss and metabolic improvements, representing a potential treatment for a condition that affects millions in China, where current diagnosis rates are low. This marks the seventh Phase 3 study for the drug.

Bombardier’s Global 7500 sets a new speed record on a flight from Montreal to Paris, completing the journey in 5 hours and 30 minutes at over 1,000 km/hr. The aircraft showcases its superior performance and ability to connect global cities swiftly. The Global 7500 consistently achieves impressive real-world results, solidifying its place as a premier business jet, with the Global 8000 on the horizon.

The EVEREST Phase 4 trial presented at the 2025 EAACI conference demonstrated that Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps and asthma. The study showed superior results for Dupixent across all endpoints for both conditions, including nasal polyp size reduction, improved smell, and enhanced lung function. This head-to-head comparison represents a significant milestone in respiratory disease treatment.

FranklinCovey is hosting a webinar on June 16, 2025, featuring Amy Edmondson, Stephen M. R. Covey, and Liz Wiseman. The discussion will delve into how leaders can thrive amidst constant disruption, addressing the leadership crisis, engagement recession, and adaptability dilemma. The event will explore strategies for navigating uncertainty and fostering successful, resilient organizations.

Upstream Bio announced promising data on verekitug, a lead candidate targeting the TSLP receptor, presented at the EAACI Congress. Modeling data suggests enhanced potency compared to tezepelumab, potentially offering a differentiated profile across inflammatory diseases like asthma, COPD, and CRSwNP. Phase 2 trials for CRSwNP are expected in Q3 2025, followed by severe asthma data in 2026’s first half.

Phase 1b/2 trial data showed that epcoritamab combined with R-ICE achieved an 87% overall response rate and a 65% complete response rate in relapsed/refractory DLBCL patients, with 65% proceeding to ASCT. These results, presented at EHA, suggest epcoritamab may improve ASCT eligibility and represent a potential new treatment option.

Johnson & Johnson announced promising results from the Phase 2 RedirecTT-1 study, which evaluated TALVEY (talquetamab) and TECVAYLI (teclistamab) in extramedullary multiple myeloma (EMD) patients. The combination therapy showed an impressive 78.9% overall response rate. These findings suggest a potential off-the-shelf treatment approach for a patient population with limited options and significant unmet needs.

Sarepta Therapeutics is taking action to address safety concerns with its gene therapy ELEVIDYS for Duchenne muscular dystrophy after a second fatal liver failure case. The company is implementing a new immunosuppression regimen, pausing shipments for non-ambulatory patients, and halting dosing in its ENVISION study. Sarepta will discuss these developments in an investor call on June 16, 2025.

Ram launched its “Never Stop Being American” campaign, promoting American culture and traditions, with the new tagline “Nothing Stops Ram.” The launch, coinciding with Flag Day, features a patriotic ad narrated by Dana White. This campaign follows the return of the HEMI V-8 engine, Ram’s comeback to NASCAR, and its role as the exclusive truck sponsor for America’s 250th-anniversary celebration.

Ready Capital Corporation announced upcoming Q2 2025 dividends. Common stockholders will receive $0.125 per share, payable July 31, 2025. Series C and E Preferred stockholders will receive $0.390625 (July 15, 2025) and $0.40625 (July 31, 2025) per share, respectively. The real estate finance firm’s strategy focuses on lower-to-middle-market commercial real estate, offering diverse loan products.